期刊
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
卷 127, 期 7, 页码 557-561出版社
SPRINGER
DOI: 10.1007/s00402-006-0243-1
关键词
heterotopic ossification; hip; arthroplasty; COX-2; rofecoxib
Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent heterotopic ossification but gastrointestinal complaints are frequently. Selective cyclooxygenase-2 (COX-2) inhibiting NSAID produce less gastrointestinal side effects. Patients and methods A prospective two-stage study design for phase 2 clinical trials with 42 patients was used to determine if rofecoxib (a COX-2 inhibitor) 50 mg oral for 7 days prevents heterotopic ossification. A cemented primary THA was inserted for osteoarthroses. After 6 months heterotopic bone formation was assessed on AP radiographs using the Brooker classification. Results No heterotopic ossification was found in 81% of the patients, 19% of the patients had Brooker grade 1 ossification. Conclusion Using a two-stage study design for phase 2 clinical trials, a 7-day treatment of a COX-2 inhibitor (rofecoxib) prevents effectively the formation of heterotopic ossification after cemented primary total hip arthroplasty.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据